References
- Gastmeier P, Kampf G, Wischnewski N, et al. Prevalence of nosocomial infections in representative German hospitals. J Hosp Infect 1998; 38: 37-49.
- Drago L, de Vecchi E, Mombelli B, Nicola L, Valli M, Gismondo MR. Activity of levofloxacin and ciprofloxacin against urinary pathogens. J Antimicrob Chemother 2001; 48: 37-45.
- Hurst M, Lamb HM, Scott LJ, Figgitt DP. Levofloxacin. An updated review of its use in the treatment of bacterial infections. Drugs 2002; 62: 2127-2167.
- Marchetti F, Viale P. Current and future perspectives for levofloxacin in severe Pseudomonas aeuginosa infections. J of Chemotherapy 2003; 15: 315-322.
- Naber KG, Bergman B, Bishop MC, Bjerklund- Johansen TE, Botto H, Lobel B, et al. The Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). EAU Guidelines for the management of urinary and male genital tract infections. Eur Urol 2001; 40: 576-588.
- Richard GA, de Abate CA, Ruoff GE, Corrado M, Fowler CL, Morgan N. A double-blind, randomized trial of the efficacy and safety of short-course, once-daily levofloxacin versus ofloxacin twice daily in uncomplicated urinary tract infections. Infect Dis Clin Pract 1998; 9: 323-329.
- Richard GA, Klimberg IN, Fowler CL, Calleryd’Amico S, Kim SS. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology 1998; 52: 51-55.
- Kalsi J, Arya M, Wilson P, Mundy A. Hospital-acquired urinary tract infection. Int J Clin Pract 2003; 57: 388-391.
- Naber CK, Hammer H, Kinzig-Schippers M, Sörgel F, Naber KG. Urinary excretion and bacterial activity of levofloxacin versus ciprofloxacin in healthy volunteers after a single oral dose of 500mg. 9th International Congress on Infectious Diseases, Buenos Aires, Argentina, 10-13 April 2000. Poster # 10920.
- Naber KG. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 2001; 17: 331-341.
- Richard GA, Childs S, Fowler C, Pittman W, et al. A comparison of levofloxacin (LVFX) and ciprofloxacin (cipro) for the treatment of complicated urinary tract infections (cUTI). Clin Infect Dis 1996; 23: 914.
- Klimberg IW, Cox CE 2nd, Fowler CL, King W, Kim SS, Callery-D’Amico S. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. Urology 1998; 51; 610-615.
- Workshop Committee of the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK . Chronic Prostatitis Workshop, Bethesda, MD, 7-8 December, 1995.
- Naber KG. Antimicrobial treatment of bacterial prostatitis. Eur Urol 2003; 43, Suppl. 2: 23-26.
- Drusano GL, Preston SL, van Guilder M, North D, Gombert M, Oefelein M, et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000; 44: 2046-2051.
- Bulitta J, Kinzig-Schippers M, Naber CK, Naber KG, Sauber C, Kleinschnitz M, et al. Limitations in the use of drug cocktails (DC) to compare pharmacokinetics (PK) of drugs: ciprofloxacin (CIP) vs. levofloxacin (LEV). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto, Ontario, Canada, Sept. 17-20, 2000, Poster #506.
- Kahn JB, Newton PA, Wu S, Bossumini L, Wiesinger BA, Tennenberg AM. The changing etiology of chronic bacterial prostatitis (CBP). 42nd ICAAC, San Diego, California, USA, September 27-30, 2002. Abstract L-1801.